New WHO Guidelines: Implications on Therapeutics and Monitoring of HIV Infections
- *Corresponding Author:
- BR. Das
President-Research & Innovation
Mentor- Molecular Pathology and Clinical Research Services
SRL Limited, Goregaon, Mumbai-400062, India
Tel: + 022-6780 1314
E-mail: [email protected]
Received date May 26, 2016; Accepted date June 13, 2016; Published date June 20, 2016
Citation: Naik S, Das BR (2016) New WHO Guidelines: Implications on Therapeutics and Monitoring of HIV Infections. HIV Curr Res 1: 102. doi: 10.4172/2572-0805.1000102
Copyright: © 2016 Naik S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The new WHO guidelines in 2015 on initiation of early antiretroviral therapy (ART) and on pre-exposure prophylaxis for HIV mark the next stage in the fight to curb the epidemic of HIV-AIDS. With ART for all, the number of people eligible for ART rises significantly. Implementation of these guidelines in the high burden, low income countries are the stepping stone to achieving the UNAIDS target of eliminating the HIV-AIDS epidemic by 2030. Scaling up of programmatic capacities globally to diagnose, treat and monitor therapy for HIV-AIDS is the need of the hour. Drug resistance may arise as a further challenge to the efficacy of therapy with the expected upsurge in ART coverage.